Compare Raymond James Financial, Inc. (RJF) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Raymond James Financial, Inc. trades at $167 (market cap $32.73B), while State Street SPDR S&P Biotech ETF trades at $151.96. The key difference: Raymond James Financial, Inc. pays a 1.29% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Raymond James Financial, Inc. nearer its low. Which is the better fit depends on your goals.
| RJF | XBI | |
|---|---|---|
Market Cap | $32.73B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $176.43 | $164.28 |
52-Week Low | $140.89 | $85.16 |
Dividend Yield | 1.29% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
